Analyst Report: Merck & Co Inc
*** Merck’s Mixed Quarter: The Blockbuster Bridge and the Post-Keytruda Strategy The pharmaceutical world is constantly focused on the next big breakthrough, but for a giant like Merck & Co. Inc., the focus in early 2026 is squarely on managing a powerhouse present while building a compelling future. Following the release of its fourth-quarter and…